$1.73 Earnings Per Share Expected for Gilead Sciences, Inc. (NASDAQ:GILD) This Quarter

Equities research analysts expect that Gilead Sciences, Inc. (NASDAQ:GILD) will announce earnings of $1.73 per share for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Gilead Sciences’ earnings, with the highest EPS estimate coming in at $1.89 and the lowest estimate coming in at $1.57. Gilead Sciences posted earnings per share of $1.91 during the same quarter last year, which suggests a negative year-over-year growth rate of 9.4%. The business is expected to announce its next quarterly earnings results on Wednesday, July 24th.

According to Zacks, analysts expect that Gilead Sciences will report full-year earnings of $6.89 per share for the current year, with EPS estimates ranging from $6.52 to $7.10. For the next year, analysts forecast that the company will report earnings of $7.11 per share, with EPS estimates ranging from $6.44 to $7.35. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.53 by $0.23. The business had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The company’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.48 earnings per share.

Several analysts have recently weighed in on the company. Mizuho restated a “buy” rating and issued a $88.00 price objective on shares of Gilead Sciences in a report on Wednesday, June 19th. JPMorgan Chase & Co. restated a “buy” rating and issued a $87.00 price objective on shares of Gilead Sciences in a report on Tuesday, May 7th. Raymond James set a $83.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Friday, May 3rd. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Monday, May 6th. Finally, BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Friday, May 24th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $79.54.

In related news, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $66.74, for a total transaction of $180,198.00. Following the transaction, the director now directly owns 57,560 shares of the company’s stock, valued at $3,841,554.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the transaction, the director now directly owns 34,669 shares in the company, valued at $2,270,126.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,018 shares of company stock valued at $1,914,428. 0.20% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of GILD. Norges Bank acquired a new position in Gilead Sciences during the fourth quarter valued at $798,882,000. Parnassus Investments CA increased its position in Gilead Sciences by 21.2% in the 1st quarter. Parnassus Investments CA now owns 13,074,555 shares of the biopharmaceutical company’s stock worth $849,976,000 after purchasing an additional 2,288,767 shares during the last quarter. BlackRock Inc. increased its position in Gilead Sciences by 2.2% in the 4th quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock worth $6,516,839,000 after purchasing an additional 2,195,948 shares during the last quarter. Two Sigma Advisers LP increased its position in Gilead Sciences by 1,406.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,104,840 shares of the biopharmaceutical company’s stock worth $69,108,000 after purchasing an additional 1,031,502 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. increased its position in Gilead Sciences by 169.8% in the 4th quarter. Los Angeles Capital Management & Equity Research Inc. now owns 1,433,324 shares of the biopharmaceutical company’s stock worth $89,654,000 after purchasing an additional 901,998 shares during the last quarter. 78.68% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Gilead Sciences stock opened at $67.56 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.53 and a current ratio of 3.62. The firm has a market capitalization of $85.52 billion, a price-to-earnings ratio of 10.99, a price-to-earnings-growth ratio of 3.13 and a beta of 1.10. The company has a fifty day moving average price of $66.14. Gilead Sciences has a fifty-two week low of $60.32 and a fifty-two week high of $79.61.

The business also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.73%. The ex-dividend date of this dividend was Thursday, June 13th. Gilead Sciences’s dividend payout ratio is 40.98%.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: What is the formula for calculating total return?

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.